Clinical Trial Matching

Tempus is an industry leader analyzing clinical and molecular data to identify actionable clinical trial options for cancer patients. Through our proprietary trial matching software and methods, we identify relevant, open, and recruiting clinical trials personalized to each patient’s molecular and clinical context.

“Tempus provides an unparalleled level of commitment and support in aligning all involved parties and streamlining the process, especially given the challenges of the COVID-19 pandemic. We ultimately met our target goal of activating our trial in just two weeks.”
Dr. Julio Peguero, Director of Research, Oncology Consultants


Precision medicine has changed the clinical research landscape

230+ clinical trials have been active targeting a wide array of biomarkers including FGFR, KEAP1, RET, NOTCH1, ESR1, and MET.

  1. Smart trial matching
    Each patient’s sequenced molecular data and clinical history are compared against each trial’s structured inclusion and exclusion criteria through our proprietary trial matching software and methods.
  2. Rapid site activation
    Tempus utilizes a standardized clinical trial agreement, rate card, feasibility process, informed consent form (ICF), and a central IRB along with a team of dedicated research liaisons to streamline activities for study start-up.
  3. Site activated in ~10 business days for just-in-time trial activation.

Trial Matching at Tempus


health systems representing 500+ sites


cancer patients covered by the TIME network


clinical trials have been active


patients have been identified for potential enrollment into clinical trials in our network


A new precision medicine approach to clinical trials

Tempus generates, organizes, and analyzes extensive amounts of data through our next-generation sequencing lab, AI-assisted clinical data structuring capabilities, and connectivity with researchers across the network. We support providers in identifying relevant and actionable clinical trials for their patients.

Our proprietary clinical trial matching software enables real-time matches for relevant, open, and recruiting clinical trials. Tempus’ team of trained abstractors manually reviews all protocol-specific inclusion and exclusion eligibility criteria for trials in the TIME Trial Program.

Request a Demo


Bringing the right clinical trial to the right patient in days instead of months

The program is designed to provide access to thousands of physicians and patients to clinical trials and novel therapeutics, no matter where they are in the United States.

All sites and sponsors participating in the TIME Trial Program commit to a standard clinical trial agreement, a pre-negotiated budget, and the use of a central IRB for trial oversight. Additionally, Tempus’ dedicated, expert research liaisons support sites and sponsors in streamlining all recruitment and enrollment activities

The entire activation process is designed to take 14 days or less, and the site always makes the decision about particular studies for involvement.

*Representative of a target timeline.
  • Patient Identified
  • Day 0 Site notified of eligible patient
  • Day 3 Clinical trial agreement signed by site and sponsor
  • Day 7 IRB approved and study materials sent
  • Day 10 Site initiation and training
  • Day 14 Patient entrolled in open trial
“The just-in-time TIME Trial model is especially beneficial for rural, underserved communities. It provides state-of-the-art targeted therapy trials and enrolls a diverse patient population in clinical trials, addressing the equity in clinical trials for all ethnic groups.”
Dr. Raju K. Vaddepally, MD, Hematology/Oncology at the Yuma Regional Medical Center Cancer Center


The TIME Trial Program activates unique clinical trials targeting a range of biomarkers at institutions across the United States.

Learn more about recent rapid activation success stories.


Highline Sciences, a specialized, full-service clinical CRO and consultancy focused on oncology, is now part of Tempus.

Learn more

This is data-driven precision medicine.

This is the future of healthcare.